This post was originally published on this site Campaigns by Movember and the Alberta Cancer Foundation have helped to raise the number of men enrolled to more than 200 in the validation study of ClarityDX Prostate, a new blood screening test developed by Nanostics for the early diagnosis of prostate cancer. Recruitment, which started in June…
This post was originally published on this site Epizyme successfully met with the U.S. Food and Drug Administration (FDA) to bolster an upcoming submission of its oral investigational treatment tazemetostat for relapsed or resistant follicular lymphoma, with or without EZH2 activating mutations. The pre-New Drug Application (NDA) meeting is a critical step to ensure a…
This post was originally published on this site With its annual essay competition, the Alzheimer’s Foundation of America (AFA) is again offering high schoolers affected by Alzheimer’s disease a chance to motivate others and earn money for college. In the AFA Teens for Alzheimer’s Awareness College Scholarship Essay Contest, college-bound high school seniors nationwide are invited…
This post was originally published on this site Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528 (JNJ-68284528), safely led to early and deep responses in all patients with relapsed or refractory multiple myeloma treated in the first part of a Phase 1/2 trial. These findings were announced in the oral presentation, “Results from…
This post was originally published on this site The Breast Cancer Index, a molecular test developed by Biotheranostics, successfully identified a group of women with hormone receptor (HR)-positive breast cancer who may benefit from long-term hormone therapy with tamoxifen, data from a Phase 3 trial shows. Study findings were presented in a poster, titled “Breast…
This post was originally published on this site [Editor’s note: This story, published on Dec. 10, was updated on Dec. 16 with additional details provided by Acadia Pharmaceuticals.] People with Alzheimer’s and other dementias treated with Nuplazid (pimavanserin) in a Phase 3 trial were almost three times less likely to have a psychosis relapse —…
This post was originally published on this site Combining bemcentinib with Keytruda (pembrolizumab) is effective and delays disease progression in people with previously treated advanced non-small cell lung cancer (NSCLC), particularly in those with AXL-positive tumors. Those updated results from a Phase 2 clinical trial show, to researchers’ surprise, that benefits also were seen in people with low levels of PD-L1…
This post was originally published on this site A record number of people are expected to travel this holiday season. The travelers will undoubtedly include familial caregivers journeying with loved ones who have dementia. These are courageous individuals, perhaps seeking one last hurrah before Alzheimer’s disease prevents them from traveling to faraway destinations. Taking a…
This post was originally published on this site A recent Phase 1 clinical study of a potential Alzheimer’s therapy showed positive results regarding both safety and biomarkers for cognitive processes. The data support advancing the investigational compound, NDX-1017, developed by Athira Pharma, to later-stage clinical trials. The results, “Phase 1 Study of NDX-1017: Safety, Pharmacokinetics and…
This post was originally published on this site After an initial rejection due to cost-effectiveness concerns, the U.K.’s National Institute of Health and Care Excellence (NICE) has reversed its decision and is expanding the use of Lynparza (olaparib) tablets to include maintenance therapy for relapsed ovarian cancer patients who responded to platinum-based chemotherapy. The recommendation is…
